Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4685 monotherapy dose-escalation study in relapsed or refractory T-cell lymphoma and CLL/SLL
jRCT2011230051Phase 1Suspended
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-4685 in T-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Nov 2023; status: suspended.
02
Drugs
ONO-4685
03
Conditions
T-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2011230051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230051.